Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. (symbol: VTGN) is a pioneering biotechnology firm committed to improving the lives of patients with central nervous system (CNS) disorders. The company leverages its advanced stem cell technology platform, which is based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed human cells. This innovative platform enables the creation of novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue, and cell therapy, providing clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
At the clinical stage, Vistagen is actively involved in developing and commercializing a robust pipeline consisting of six product candidates. Five of these candidates are clinical-stage investigational agents known as pherines, which represent a new class of drugs. Notable products within their portfolio include:
- PH94B: A novel neuroactive nasal spray designed to treat social anxiety disorder.
- PH10: An odorless, fast-acting synthetic neurosteroid aimed at addressing major depressive disorder (MDD).
- AV-101: An oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR), which is being developed to treat MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy.
Vistagen's innovative approach and dedication to CNS disorders position it as a significant player in the biotechnology sector. The company is continually making strides in its research and clinical trials, striving to bring groundbreaking therapies to market. Investors and stakeholders can look forward to Vistagen's ongoing developments and potential future successes as it targets unmet medical needs with its cutting-edge technologies and therapeutic candidates.
VistaGen Therapeutics (NASDAQ: VTGN) has scheduled a conference call for June 23, 2022, at 2:00 PM PT to discuss its fiscal year 2022 financial results, ending March 31, 2022. The call will also cover recent achievements and future milestones. The company is focused on advancing therapeutics for anxiety and depression, particularly its lead candidate, PH94B, a nasal spray currently in Phase 3 trials in the U.S. Results are expected in 2022. If successful, PH94B could become the first FDA-approved rapid treatment for social anxiety.
VistaGen Therapeutics, Inc. (Nasdaq: VTGN) announced the acceptance of an abstract for its Phase 2A clinical trial studying PH94B, a rapid-onset nasal spray for anxiety disorders, at the ASCP Annual Meeting from May 31 to June 3, 2022. The trial focuses on adjustment disorder with anxiety (AjDA), aiming to evaluate efficacy and safety. PH94B is noted for its unique mechanism, intended to offer rapid relief from anxiety symptoms. CEO Shawn Singh emphasized the increasing mental health challenges and the demand for innovative treatments amidst this urgent need.
VistaGen Therapeutics (Nasdaq: VTGN) announced participation in two upcoming investor conferences in June: the William Blair 42nd Annual Growth Stock Conference on June 7 at 2:00 PM CT in Chicago, and the Jefferies Global Healthcare Conference on June 9 at 10:00 AM ET in New York. CEO Shawn Singh will engage in discussions aimed at transforming treatment for anxiety and depression. The company’s lead candidate, PH94B, is positioned to be a leading fast-acting treatment for social anxiety disorder, currently undergoing Phase 3 trials in the U.S.
VistaGen Therapeutics (Nasdaq: VTGN) announced that the FDA confirmed there is no signal of abuse potential for its investigational treatment PH94B, designed for acute treatment of adults with social anxiety disorder (SAD). Based on completed clinical and nonclinical data, the FDA stated additional studies to assess abuse potential are unnecessary, and a human abuse potential study is not needed at this time. VistaGen is advancing PH94B through its Phase 3 PALISADE program. With over 25 million affected in the U.S., effective treatment options are critical for those suffering from SAD.
VistaGen Therapeutics (Nasdaq: VTGN) has appointed Reid Adler as its new Chief Legal Officer. Adler brings over three decades of legal experience and has previously served as outside counsel for the company. He will oversee legal affairs and provide strategic guidance to VistaGen’s Executive Team and Board. CEO Shawn Singh expressed confidence in Adler's leadership, emphasizing the company's commitment to transforming mental health treatment. VistaGen focuses on advancing therapeutics for anxiety and depression, aiming to launch faster-acting treatments with fewer side effects.
VistaGen Therapeutics (Nasdaq: VTGN) announced the presentation of preclinical data at significant scientific meetings, emphasizing the unique mechanism of action (MOA) of their candidate PH94B, aimed at treating social anxiety disorder (SAD). Notably, PH94B's anxiolytic properties do not require systemic uptake, reducing side effect risks. Researchers will showcase findings on April 30 and during the ASCP meeting in June 2022. VistaGen is currently conducting Phase 3 trials for PH94B, seeking to address the rising mental health crisis effectively.
VistaGen Therapeutics (NASDAQ: VTGN) and AffaMed Therapeutics have completed regulatory preparations for the PALISADE Global Phase 3 clinical trial of PH94B. This trial will assess the efficacy, safety, and tolerability of PH94B, a nasal spray, for treating social anxiety disorder (SAD) in adults. Expected to initiate in the second half of 2022, the trial aims to support commercialization in China and other markets outside the U.S. The trial design is based on previous PALISADE studies, with initial results anticipated by mid-2024.
VistaGen Therapeutics (Nasdaq: VTGN), a biopharmaceutical company focused on CNS disorders, announced that CEO Shawn Singh will participate in a fireside chat with Maxim Analyst Jason McCarthy on March 28, 2022, at 2:00 p.m. PT during the Maxim Group 2022 Virtual Growth Conference. In addition, a recorded corporate presentation highlighting its pipeline and milestones will be available to registered attendees from March 28, 2022, 6:00 a.m. PT. VistaGen is developing PH94B, a nasal spray for acute anxiety treatment, currently in Phase 3 trials.
VistaGen Therapeutics (Nasdaq: VTGN) reports progress in its late-stage clinical programs for PH94B, targeting social anxiety disorder (SAD), with topline data from PALISADE-1 and PALISADE-2 trials expected in mid-2022 and the second half of 2022, respectively. The company has initiated the PALISADE Long-term Safety Study and a Phase 2A trial for adjustment disorder with anxiety (AjDA). Additionally, a Phase 2B study for PH10 in major depressive disorder (MDD) is set to commence in late 2022. The net loss for Q3 2022 was approximately $10.5 million, with cash reserves of $83.7 million as of December 31, 2021.
VistaGen Therapeutics (NASDAQ: VTGN) announced a conference call scheduled for February 10, 2022, at 2:00 PM PT to discuss its financial results for the third quarter of fiscal year 2022, which ended December 31, 2021. The call aims to review recent accomplishments and outline upcoming milestones for the company, focusing on its commitment to developing innovative medicines for CNS disorders. A live audio webcast will be accessible, and a recorded playback will be available afterward.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
What does Vistagen Therapeutics, Inc. specialize in?
What is the company's main technological focus?
What are pherines?
Can you name some of Vistagen Therapeutics' key products?
What is PH94B used for?
What is PH10?
What conditions is AV-101 aimed at treating?
How does Vistagen's stem cell technology benefit drug development?
Is Vistagen Therapeutics currently in the clinical stage?
Where can I find the latest news about Vistagen Therapeutics, Inc.?
